In vitro activity of BAY v 3522, a new cephalosporin for oral administration | Zendy

Teri L. Hodges | Zendy; G M Eliopoulos | Zendy; K Klimm | Zendy; Robert C. Moellering | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of BAY v 3522, a new cephalosporin for oral administration

Author(s) -

Teri L. Hodges,

G M Eliopoulos,

K Klimm,

Robert C. Moellering

Publication year - 1990

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.34.9.1849

Subject(s) - cefaclor , cefuroxime , cefixime , cephradine , ciprofloxacin , cephalosporin , bay , amoxicillin , cefdinir , ampicillin , cefadroxil , antibiotics , medicine , erythromycin , microbiology and biotechnology , biology , civil engineering , engineering

The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research